2024 World Conference on Lung Cancer (WCLC) - Posters-P2.11A.03 Association of LIPI with Patterns of Response, Resistance, and Survival in Patients with Metastatic NSCLC Treated with PD(L)-1 Blockade

P2.11A.03 Association of LIPI with Patterns of Response, Resistance, and Survival in Patients with Metastatic NSCLC Treated with PD(L)-1 Blockade

Back to course

Pdf Summary

The study explores the potential of the Lung Immune Prognostic Index (LIPI) as a predictor for response and resistance in patients with metastatic non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs), specifically PD-(L)1 blockade. Despite the effectiveness of PD-(L)1 therapy for many patients, a significant proportion still exhibit resistance, necessitating the identification of accessible, simple predictors for response outcomes.<br /><br />Conducted as a retrospective cohort study between 2017 and 2022, the research aimed to establish a correlation between LIPI scores and clinical outcomes, such as primary and acquired resistance, long-term response, progression-free survival (PFS), and overall survival (OS). LIPI, a measure indicating systemic host inflammation, was examined for its predictive capabilities regarding treatment resistance patterns and patient survival outcomes.<br /><br />The findings demonstrated that a favorable LIPI score significantly correlated with extended long-term response, PFS, and OS. Specifically, a good LIPI was linked to long-term response with an unadjusted odds ratio (uOR) of 4.62, indicating a strong association between higher LIPI scores and better survival outcomes. These associations affirm LIPI's role as a non-invasive and practical tool for predicting the therapeutic response to ICIs beyond merely serving as an immunotherapy response marker.<br /><br />The conclusion emphasizes the necessity for further prospective studies to corroborate these findings and potentially expand the application of LIPI in clinical practices. Overall, the research supports the application of LIPI as an essential tool in identifying NSCLC patients most likely to benefit from PD-(L)1 therapies, enhancing personalized treatment strategies and outcomes.

Asset Subtitle

ENRIQUE CABALLE

Meta Tag

Speaker ENRIQUE CABALLE

Topic Metastatic NSCLC – Immunotherapy

Keywords

Lung Immune Prognostic Index

metastatic non-small cell lung cancer

immune checkpoint inhibitors

PD-(L)1 blockade

treatment resistance

progression-free survival

overall survival

systemic inflammation

retrospective cohort study

personalized treatment